EvergreenHealth's Booth Gardner Parkinson's Care Center is conducting a phase 3, double-blind, placebo-controlled study to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease
Who may be eligible to participate?
Male or female, age 40 to 80 years who have been diagnosed with Parkinson's disease (PD) within 3 years of the screening visit. Other inclusion/exclusion criteria apply.
What does participation involve?
- Subjects will be randomized to receive either tavapadon or placebo, once daily.
- The trial will include a Screening Period (maximum of 4 weeks), a 27-week Treatment Period, a 10-day Safety/Withdrawal Assessment Period, and a 20-day Safety Follow-up Period
- Each subject will participate in the study for up to approximately 35 weeks.
EvergreenHealth's Study ID